Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
14 hedge funds and large institutions have $1.52M invested in Interpace Biosciences, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
7% less funds holding
Funds holding: 15 → 14 (-1)
61% less capital invested
Capital invested by funds: $3.9M → $1.52M (-$2.38M)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Penbrook Management
New York
|
+$434K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.28K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$5.21K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$259 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$924K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$439K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$127K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$57K |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$37.2K |
IDXG Hedge Fund Activity: Q2 2020 in Review
14 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2020, worth a combined $1.52M — down 61% from $3.9M a quarter earlier.
Fund positioning in IDXG was balanced in Q2 2020: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Penbrook Management, opening a new position worth an estimated $434K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $924K sold.
- 14 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2020, down from 15 in Q1 2020.
- Funds reported $1.52M of Interpace Biosciences, Inc. Common Stock stock for Q2 2020, down 61% quarter-over-quarter.
- 4 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2020 and 4 closed out, a net change of 0 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q2 2020 was Penbrook Management, an estimated $434K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2020 was Stonepine Capital Management, an estimated $924K sold.
Based on aggregated 13F filings for Q2 2020.